Pharmacology and mechanism: what is actually known

Phenotropil is clinically used in its racemic form — an equal mixture of R and S enantiomers around the single stereocentre at C4 of the pyrrolidinone ring. The 2011 stereoselectivity study found the split is real: the R-enantiomer improves memory in passive-avoidance testing while the S-enantiomer does not; antidepressant and locomotor effects rely on both enantiomers; and brain concentrations of the two are similar — so the potency difference is pharmacodynamic, not an exposure artefact.[7]

The S-enantiomer then produced the paradox of the series: described as a selective dopamine transporter inhibitor that does not influence norepinephrine or serotonin receptors, it reduced body-weight gain and improved glucose handling in obese Zucker rats and Western-diet mice — without increasing locomotor activity. A stimulant-family molecule that does not stimulate.[9]

Merz Pharmaceuticals characterised the R-enantiomer as MRZ-9547: DAT binding IC50 of 4.82 µM, dopamine-uptake inhibition IC50 of 14.5 µM in human recombinant transporter cells, about 38-fold weaker at the norepinephrine transporter — with moderate stimulation of striatal dopamine release in vivo. In effort-based choice tasks, MRZ-9547 increased responding beyond methylphenidate, modafinil and amphetamine comparators; Merz pursued it for fatigue and motivational deficits in Parkinson’s disease and depression.[8]

In 2020, the Latvian Institute of Organic Synthesis ran a radioligand target-profiling screen and found DAT to be the only significant molecular target of R-phenylpiracetam. The compound reached mouse brain within 15 minutes of both intraperitoneal and oral dosing (brain Cmax 28 and 18 µg/g) and showed anti-inflammatory and neuroprotective effects in LPS endotoxaemia and carrageenan/formalin models.[10]

Search the secondary web and you will find phenylpiracetam described as an AMPA-receptor modulator. The primary record does not contain that claim: a PubMed search for phenylpiracetam and AMPA returns zero results (checked live, 2026-08-15). AMPA potentiation is documented for other racetams — piracetam and aniracetam — and the often-cited 2001 Molecular Pharmacology nicotinic paper concerns nefiracetam and aniracetam, not phenylpiracetam. The claim migrated here by class extrapolation; this site declines to carry it.[14][5]

Class-level humility, from the literature itself: “the modes of action of piracetam and most of its derivatives remain an enigma” (Malykh & Sadaie 2010), and the classic 1994 review found no high affinity for any tested receptor across the class. Carphedon’s DAT pharmacology is the exception that was actually measured — at micromolar concentrations, in cells and rodents.[12][13]

Here is the gap the marketing never mentions: the human pharmacokinetics of phenylpiracetam have never been published in the indexed literature. The circulating numbers — roughly complete oral bioavailability, a 3–5 hour half-life, about 40% renal excretion unchanged — trace to Russian product labelling, not to peer-reviewed clinical PK studies. Whether therapeutic plasma or brain concentrations in humans ever reach the micromolar range where DAT and α4β2 binding were measured is unknown: no human PET or occupancy study exists. The mechanism of the racemate as actually dosed in humans is unresolved.[12][10]

What this site can state: DAT inhibition is measured, enantiomer-selective, and consistent with the WADA stimulant listing. What it cannot state: that this mechanism explains any human clinical effect. Both sentences are the record.